# EDGAR Filing Document

**Accession Number:** 0001422142
**File Stem:** 0000935836-26-000289
**Filing Date:** 2026-5
**Character Count:** 17879
**Document Hash:** 37f9c11bad1b08c9342b6e946b7e05d4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000935836-26-000289.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0000935836-26-000289

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Whitehawk Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001422142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 611547850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-83932
- **FILM NUMBER:** 26995462

**BUSINESS ADDRESS:**
- **STREET 1:** 2 HEADQUARTERS PLAZA
- **STREET 2:** EAST BUILDING, 11TH FLOOR
- **CITY:** MORRISTOWN
- **STATE:** NJ
- **ZIP:** 07960
- **BUSINESS PHONE:** 551-321-2234

**MAIL ADDRESS:**
- **STREET 1:** 2 HEADQUARTERS PLAZA
- **STREET 2:** EAST BUILDING, 11TH FLOOR
- **CITY:** MORRISTOWN
- **STATE:** NJ
- **ZIP:** 07960

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aadi Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20210826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerpio Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20170316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZETA ACQUISITION CORP II
- **DATE OF NAME CHANGE:** 20071227
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACUTA CAPITAL PARTNERS, LLC
- **CENTRAL INDEX KEY:** 0001582844

**ORGANIZATION NAME:**
- **EIN:** 452817402
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 255 SHORELINE DRIVE
- **STREET 2:** SUITE 515
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-486-0581

**MAIL ADDRESS:**
- **STREET 1:** 255 SHORELINE DRIVE
- **STREET 2:** SUITE 515
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Longwood Capital Partners LLC
- **DATE OF NAME CHANGE:** 20130730

## Exhibit 99.1

EXHIBIT 99.1

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Acuta Capital Partners, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

Dated: May 18, 2026

---

| |
|:---|
| &nbsp;&nbsp; **ACUTA CAPITAL PARTNERS, LLC**<br>By: */s/ Scott R. Smith*<br> Scott R. Smith, Chief Operating Officer<br>|
| &nbsp;&nbsp; **ACUTA CAPITAL FUND, LP<br>** <br> By: Acuta Capital Partners, LLC,<br> General Partner<br>By: */s/ Scott R. Smith*<br> Scott R. Smith, Chief Operating Officer<br>|
| &nbsp;&nbsp; <br> */s/ Anupam Dalal*<br> Anupam Dalal |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Whitehawk Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Scott R. Smith**<br>255 SHORELINE DRIVE<br>SUITE 515<br>REDWOOD CITY CA 94065<br>650-486-0581

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/14/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ACUTA CAPITAL PARTNERS, LLC** | Name of reporting person<br>**ACUTA CAPITAL PARTNERS, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4685912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4685912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4685912.00** | Aggregate amount beneficially owned by each reporting person<br>**4685912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.7%** | Percent of class represented by amount in Row (11)<br>**8.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** Percentage calculated based on 53,783,329 shares of Common Stock outstanding following the closing of the private placement of the Issuer's Common Stock on May 14, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ANUPAM DALAL** | Name of reporting person<br>**ANUPAM DALAL** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**157863.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4685912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**157863.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4685912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4843775.00** | Aggregate amount beneficially owned by each reporting person<br>**4843775.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.0%** | Percent of class represented by amount in Row (11)<br>**9.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Percentage calculated based on 53,783,329 shares of Common Stock outstanding following the closing of the private placement of the Issuer's Common Stock on May 14, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Acuta Capital Fund, LP** | Name of reporting person<br>**Acuta Capital Fund, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3538288.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3538288.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3538288.00** | Aggregate amount beneficially owned by each reporting person<br>**3538288.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.6%** | Percent of class represented by amount in Row (11)<br>**6.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage calculated based on 53,783,329 shares of Common Stock outstanding following the closing of the private placement of the Issuer's Common Stock on May 14, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Whitehawk Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2 HEADQUARTERS PLAZA, EAST BUILDING, 11TH FLOOR, MORRISTOWN, NJ, 07960

**Item 4. Purpose of Transaction**

The reporting persons are filing this Schedule 13D because Mr. Dalal is on the Issuer's board of directors.  The reporting persons acquired the Stock for investment purposes based on their belief that the Common Stock, when purchased, was undervalued and represented an attractive investment opportunity.  The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional Common Stock in the open market, through privately negotiated transactions with third parties or otherwise, and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the Common Stock that they now own or hereafter acquire. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the Common Stock or pledge their interests in the Common Stock to obtain liquidity. In addition, from time to time the reporting persons and their representatives and advisers may communicate with other stockholders, industry participants and other interested parties about the Issuer.

The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders. Any such actions could involve one or more of the events referred to in clauses (a) through (j) of Item 4 of Schedule 13D, including, potentially, one or more mergers, consolidations, sales or acquisitions of assets, changes in control, issuances, purchases, dispositions or pledges of securities or other changes in capitalization.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Aggregate number of shares beneficially owned by the reporting persons:

Acuta:  4,685,912

Anupam Dalal:  4,843,775

Partnership:  3,538,288

Aggregate percentage of the class of Common Stock beneficially owned by the reporting persons:

Acuta:  8.7%

Anupam Dalal:  9.0%

Partnership:  6.6%

**(b)**
Number of shares as to which the each reporting person has:

(i)  Sole power to vote or to direct the vote:

Acuta:  0

Anupam Dalal:  157,863

Partnership:  0

(ii)  Shared power to vote or to direct the vote:

Acuta:  4,685,912

Anupam Dalal:  4,685,912

Partnership:  3,538,288

(iii)  Sole power to dispose or to direct the disposition of:

Acuta:  0

Anupam Dalal:  157,863

Partnership:  0

(iv)  Shared power to dispose or to direct the disposition of:

Acuta:  4,685,912

Anupam Dalal:  4,685,912

Partnership:  3,538,288

**(c)**
The Funds purchased 1,275,510 shares of the Issuer's Common Stock from the Issuer in a private placement that closed on May 14, 2026, for a purchase price of $3.92.  The Partnership purchased 1,002,800 of those shares.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The reporting persons' responses to Item 6 of the Schedule 13D is hereby supplemented as follows:

Securities Purchase Agreement

On May 12, 2026, the Funds entered into a Securities Purchase Agreement with the Issuer (the "Purchase Agreement") pursuant to which the Issuer agreed to sell 1,275,510 shares of the Issuer's Common Stock for a purchase price of $3.92.  This purchase was part of a larger transaction (the "PIPE Financing") entered into by the Issuer with the Funds and other investors (the "PIPE Investors") pursuant to which the Issuer agreed to sell to the PIPE Investors shares of Common Stock and pre-funded warrants to acquire Common Stock.

At the closing of the PIPE Financing, the Issuer entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the PIPE Investors.  Pursuant to the Registration Rights Agreement, the Issuer will prepare and file a resale registration statement with the SEC on or prior to 30 days following the closing of the PIPE Financing. The Issuer will use its commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 60 calendar days following the closing of the PIPE Financing (or within 90 calendar days following the closing of the PIPE Financing if the SEC reviews such registration statement), subject to acceleration under certain circumstances.

The Issuer also agreed, among other things, to indemnify each participating holder, their officers, directors, members, employees, and agents, successors and assigns, and each other person, if any, who controls such participating holder within the meaning of the Securities Act of 1933, under the registration statement against certain losses, claims, damages, liabilities and expenses incident to the Issuer's obligations under the Registration Rights Agreement.

The foregoing summary of the Purchase Agreement and the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the forms of Subscription Agreement and Registration Rights Agreement, which are included as Exhibits 99.5 and 99.6, respectively hereto, and are incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ACUTA CAPITAL PARTNERS, LLC

**Signature:** /s/ Scott R. Smith

**Name/Title:** Chief Operating Officer

**Date:** 05/18/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ANUPAM DALAL

**Signature:** /s/ Anupam Dalal

**Name/Title:** Reporting person

**Date:** 05/18/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Acuta Capital Fund, LP

**Signature:** /s/ Scott R. Smith

**Name/Title:** Chief Operating Officer of the General Partner, Acuta Capital Partners, LLC

**Date:** 05/18/2026